http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03++Filed+by%3A+SAPIRSTEIN+JAMES/26598915.html si-local-file:///var/storage/secattach/20260603/26598915.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03++Filed+by%3A+SAPIRSTEIN+JAMES/26598915.html Wed, 03 Jun 2026 16:11:00 -0400 COCP O.06705893 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03++Filed+by%3A+SAPIRSTEIN+JAMES/26598915.html si-local-file:///var/storage/secattach/20260603/26598915.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03++Filed+by%3A+SAPIRSTEIN+JAMES/26598915.html Wed, 03 Jun 2026 16:11:00 -0400 COCP O.06705893 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03++Filed+by%3A+SAPIRSTEIN+JAMES/26598898.html si-local-file:///var/storage/secattach/20260603/26598898.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03++Filed+by%3A+SAPIRSTEIN+JAMES/26598898.html Wed, 03 Jun 2026 16:10:00 -0400 COCP O.06705893 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03++Filed+by%3A+SAPIRSTEIN+JAMES/26598898.html si-local-file:///var/storage/secattach/20260603/26598898.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03++Filed+by%3A+SAPIRSTEIN+JAMES/26598898.html Wed, 03 Jun 2026 16:10:00 -0400 COCP O.06705893 http://www.streetinsider.com/Corporate+News/Cocrystal+Pharma+names+James+Sapirstein+as+chief+executive+officer/26595288.html <p>Cocrystal Pharma Inc. (NASDAQ: COCP) appointed James Sapirstein as chief executive officer, effective immediately, according to a company statement. The biotechnology company also plans to add Sapirstein to its board of directors.</p><p>Sapirstein replaces Sam Lee and Jim Martin, who previously served as co-chief executive officers. Lee will continue as president and transition to chief scientific officer, while Martin will remain as chief financial officer.</p><p>The new CEO brings experience from leadership roles at several pharmaceutical companies. He previously served as chief executive officer of Contravir Pharmaceuticals and founding chief executive officer of Tobira Therapeutics. Sapirstein also held the position of executive http://www.streetinsider.com/Corporate+News/Cocrystal+Pharma+names+James+Sapirstein+as+chief+executive+officer/26595288.html Wed, 03 Jun 2026 07:03:24 -0400 COCP http://www.streetinsider.com/Management+Changes/Cocrystal+Pharma+names+James+Sapirstein+as+chief+executive+officer/26595288.html <p>Cocrystal Pharma Inc. (NASDAQ: COCP) appointed James Sapirstein as chief executive officer, effective immediately, according to a company statement. The biotechnology company also plans to add Sapirstein to its board of directors.</p><p>Sapirstein replaces Sam Lee and Jim Martin, who previously served as co-chief executive officers. Lee will continue as president and transition to chief scientific officer, while Martin will remain as chief financial officer.</p><p>The new CEO brings experience from leadership roles at several pharmaceutical companies. He previously served as chief executive officer of Contravir Pharmaceuticals and founding chief executive officer of Tobira Therapeutics. Sapirstein also held the position of executive http://www.streetinsider.com/Management+Changes/Cocrystal+Pharma+names+James+Sapirstein+as+chief+executive+officer/26595288.html Wed, 03 Jun 2026 07:03:24 -0400 COCP http://www.streetinsider.com/Hot+Corp.+News/Cocrystal+Pharma+names+James+Sapirstein+as+chief+executive+officer/26595288.html <p>Cocrystal Pharma Inc. (NASDAQ: COCP) appointed James Sapirstein as chief executive officer, effective immediately, according to a company statement. The biotechnology company also plans to add Sapirstein to its board of directors.</p><p>Sapirstein replaces Sam Lee and Jim Martin, who previously served as co-chief executive officers. Lee will continue as president and transition to chief scientific officer, while Martin will remain as chief financial officer.</p><p>The new CEO brings experience from leadership roles at several pharmaceutical companies. He previously served as chief executive officer of Contravir Pharmaceuticals and founding chief executive officer of Tobira Therapeutics. Sapirstein also held the position of executive http://www.streetinsider.com/Hot+Corp.+News/Cocrystal+Pharma+names+James+Sapirstein+as+chief+executive+officer/26595288.html Wed, 03 Jun 2026 07:03:24 -0400 COCP http://www.streetinsider.com/Hot+Mgmt+Changes/Cocrystal+Pharma+names+James+Sapirstein+as+chief+executive+officer/26595288.html <p>Cocrystal Pharma Inc. (NASDAQ: COCP) appointed James Sapirstein as chief executive officer, effective immediately, according to a company statement. The biotechnology company also plans to add Sapirstein to its board of directors.</p><p>Sapirstein replaces Sam Lee and Jim Martin, who previously served as co-chief executive officers. Lee will continue as president and transition to chief scientific officer, while Martin will remain as chief financial officer.</p><p>The new CEO brings experience from leadership roles at several pharmaceutical companies. He previously served as chief executive officer of Contravir Pharmaceuticals and founding chief executive officer of Tobira Therapeutics. Sapirstein also held the position of executive http://www.streetinsider.com/Hot+Mgmt+Changes/Cocrystal+Pharma+names+James+Sapirstein+as+chief+executive+officer/26595288.html Wed, 03 Jun 2026 07:03:24 -0400 COCP http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Press+Releases/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html <p align="justify">BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin http://www.streetinsider.com/Globe+Newswire/Cocrystal+Pharma+Appoints+James+Sapirstein%2C+Biopharma+Industry+Leader+with+Extensive+Antiviral+Development+Experience%2C+as+Chief+Executive+Officer/26595168.html Wed, 03 Jun 2026 07:00:00 -0400 A.28748976 A.41505070 COCP O.06705893 O.19888449 O.20982957 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03/26595233.html si-local-file:///var/storage/secattach/20260603/26595233.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03/26595233.html Wed, 03 Jun 2026 07:00:00 -0400 COCP O.06705893 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03/26595233.html si-local-file:///var/storage/secattach/20260603/26595233.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cocrystal+Pharma%2C+Inc.++++For%3A+Jun+03/26595233.html Wed, 03 Jun 2026 07:00:00 -0400 COCP O.06705893 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cocrystal+Pharma%2C+Inc.+++++++++++++++/26558449.html si-local-file:///var/storage/secattach/20260527/26558449.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cocrystal+Pharma%2C+Inc.+++++++++++++++/26558449.html Wed, 27 May 2026 16:32:00 -0400 COCP O.06705893 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cocrystal+Pharma%2C+Inc.+++++++++++++++/26558449.html si-local-file:///var/storage/secattach/20260527/26558449.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cocrystal+Pharma%2C+Inc.+++++++++++++++/26558449.html Wed, 27 May 2026 16:32:00 -0400 COCP O.06705893 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Cocrystal+Pharma%2C+Inc.++++For%3A+May+27/26558421.html si-local-file:///var/storage/secattach/20260527/26558421.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Cocrystal+Pharma%2C+Inc.++++For%3A+May+27/26558421.html Wed, 27 May 2026 16:31:00 -0400 COCP O.06705893